IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
University of Milan, Milan, Italy.
Obes Surg. 2024 Nov;34(11):4232-4243. doi: 10.1007/s11695-024-07523-8. Epub 2024 Oct 15.
This systematic review aims to evaluate the current evidence regarding safety and efficacy of magnetic sphincter augmentation (MSA) for the treatment of gastroesophageal reflux disease (GERD) after laparoscopic sleeve gastrectomy (LSG). Conversion to Roux-en-Y gastric bypass (RYGB) carries the risk of surgical and metabolic complications and may be contraindicated in patients with normalized or near-normalized body mass index. The LINX™ procedure aims to restore LES competency and to repair the crura. We included 109 patients (14 studies) undergoing LINX™ implant after LSG. Median follow-up was 18.9 months (range 0.3-63). Both the GERD-HRQL (38 ± 13 vs. 10 ± 11; p = 0.0078) and daily PPI use (97.4% vs. 25.3%; p < 0.0001) were significantly improved. Overall, 31.8% of the patients experienced device-related adverse events, mainly self-limiting. LINX™ explant for esophageal erosion occurred in 0.9% of the patients.
本系统评价旨在评估腹腔镜袖状胃切除术 (LSG) 后磁括约肌增强术 (MSA) 治疗胃食管反流病 (GERD) 的安全性和有效性的现有证据。转为 Roux-en-Y 胃旁路术 (RYGB) 存在手术和代谢并发症的风险,并且可能不适合体重指数正常或接近正常的患者。LINX™ 手术旨在恢复 LES 功能并修复膈脚。我们纳入了 109 例接受 LSG 后 LINX™ 植入的患者(14 项研究)。中位随访时间为 18.9 个月(范围 0.3-63)。GERD-HRQL(38±13 与 10±11;p=0.0078)和每日 PPI 使用(97.4%与 25.3%;p<0.0001)均显著改善。总体而言,31.8%的患者出现与器械相关的不良事件,主要为自限性。0.9%的患者发生食管糜烂的 LINX™ 取出。